We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Generic-Maker Aurobindo for GMP Violations in Letter
FDA Warns Generic-Maker Aurobindo for GMP Violations in Letter
June 7, 2011
The FDA has warned Indian generic-drug company Aurobindo Pharma for good manufacturing practice (GMP) violations and is requesting a detailed action plan for improving packaging and labeling compliance.